Toward common mechanisms for risk factors in Alzheimer's syndrome

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 3 - Trang 571-578 - 2017
Miguel Medina1,2, Zaven S. Khachaturian3, Martin Rossor4, Jesús Avila1,5, Angel Cedazo-Minguez6
1CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), ISCIII, Madrid, Spain
2CIEN Foundation, Reina Sofia Foundation Alzheimer Center, Madrid, Spain
3PAD2020, Potomac, MD, USA
4Institute of Neurology, University College London, London, UK
5Neurobiology Laboratory, Center for Molecular Biology “Severo Ochoa” CSIC-UAM, Madrid, Spain
6Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden

Tóm tắt

AbstractThe global strategic goal of reducing health care cost, especially the prospects for massive increases due to expanding markets for health care services demanded by aging populations and/or people with a wide range of chronic disorders‐disabilities, is a complex and formidable challenge with many facets. Current projections predict marked increases in the demand for health driven by both the exponential climb in the prevalence of chronic disabilities and the increases in the absolute numbers of people in need of some form of health care. Thus, the looming predicament for the economics of health care systems worldwide mandates the formulation of a strategic goal to foster significant expansion of global R&D efforts to discover and develop wide‐ranging interventions to delay and/or prevent the onset of chronic disabling conditions. The rationale for adopting such a tactical objective is based on the premise that the costs and prevalence of chronic disabling conditions will be reduced by half even if a modest delay of 5 years in the onset of disability is obtained by a highly focused multinational research initiative. Because of the recent history of many failures in drug trials, the central thesis of this paper is to argue for the exploration‐adoption of novel mechanistic ideas, theories, and paradigms for developing wide range and/or types of interventions. Although the primary focus of our discussion has been on biological approaches to therapy, we recognize the importance of emerging knowledge on nonpharmacological interventions and their potential impact in reducing health care costs. Although we may not find a drug to cure or prevent dementia for a long time, research is starting to demonstrate the potential contributes of nonpharmacological interventions toward the economics of health care in terms of rehabilitation, promoting autonomy, and potential to delay institutionalization, thus promoting healthy aging and reductions in the cost of care.

Tài liệu tham khảo

Khachaturian Z.S., 2012, Perspectives on Alzheimer's disease: past, present and future, 179 OECD.Emerging Trends in Biomedicine and Health Technology Innovation: Addressing the Global Challenge of Alzheimer's June 14 2013‐OECD Science Technology and Industry Policy Papers2013 Available at:https://doi.org/10.1787/5k44zcpt65vc‐en. Accessed May 14 2015. 10.1126/science.1566067 10.1038/nn.4017 10.1038/nn.4018 10.1056/NEJMoa1202753 10.1016/j.ajpath.2015.09.018 10.1016/S1474-4422(14)70136-X Rossor M., 2015, Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia?, Lancet, 86, 1008, 10.1016/S0140-6736(15)60248-3 10.1073/pnas.1522683112 10.1101/cshperspect.a006296 10.1016/0197-4580(87)90073-X 10.1016/j.jalz.2016.12.006 10.1073/pnas.91.23.11183 10.1586/ern.11.36 10.1016/j.bpj.2009.02.036 10.1212/WNL.45.6.1092 10.1159/000026149 10.1111/j.1582-4934.2007.00130.x 10.1016/j.mam.2009.02.001 10.1194/jlr.M300320-JLR200 10.3233/JAD-2011-101512 10.1074/jbc.M111.236877 10.1111/j.1750-3639.2008.00174.x 10.1016/j.neuron.2004.09.010 10.1111/joim.12192 10.1016/S1474-4422(16)00062-4 10.1007/s11682-012-9196-x Calero M., 2015, Additional mechanisms conferring genetic susceptibility to Alzheimer's disease Front, Cell Neurosci, 9, 138 10.1111/acel.12281 10.3389/fnagi.2015.00099 10.1111/j.1749-6632.1994.tb44398.x 10.1038/tp.2014.92 10.1056/NEJMra0802968 10.1016/j.yexcr.2011.12.001 10.1038/nrg3352 10.1038/nature10113 10.1038/nature08494 Parcerisas A., 2014, Somatic signature of brain‐specific single nucleotide variations in sporadic Alzheimer's disease, J Alzheimers Dis, 42, 1357, 10.3233/JAD-140891 10.1016/j.jalz.2015.02.007 10.1371/journal.pone.0101412 Gómez‐Ramos A., 2015, Distinct X‐chromosome SNVs from some sporadic AD samples, Sci Rep, 5, 18012, 10.1038/srep18012 10.1038/nature10531 10.1016/j.cell.2012.09.035 10.1126/science.1243472 10.1038/gim.2015.117 Hooly B., 2016, Developing Therapuetics for Alzheimer's disease, 23, 10.1016/B978-0-12-802173-6.00002-2 10.1016/j.jalz.2015.10.002 Khachaturian Z.S., 2016, The paradox of research on dementia‐Alzheimer's disease, J Prev Alz Dis, 3, 189 10.1016/j.neurol.2016.05.002 10.1016/S1474-4422(16)30282-4 10.1016/j.pneurobio.2015.07.003
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 3

571-578

Thông tin tác giả